Jan 28, 2026
Antibody–drug conjugates have moved into a major focus across oncology pipelines. The ADC approach pairs targeted delivery with potent payloads, and less off-target effects than standard of care (chemotherapy), which shows tremendous clinical value. Now, maturing programs are shifting focus from discovery to CMC.
Leading conversations are topics on sourcing constraints, difficulty with scale-up while maintaining consistency, complex analytical methods, and the difference in treatment of fill-finishes compared to standard biologics - all aspects of CMC. As many companies move to the outsourced development and manufacturing model, using CDMOs, these technical complexities are even more relevant to manage. Shifting the discussion to having unified CMC and quality management, consistent reliable technology transfer and supply chain design, all easier with one-stop shop CDMOs. Colocation of all integral aspects, reduces transport risks, simplifies coordination and maintains consistency across development stages. Ensuring quality systems, CDMO management and processes are up to standards is key to success.
In summary: ADC development requires a system-level approach. Treating individual elements of this process in isolation creates gaps that tend to surface later and programs that align conjugation strategy, analytical methods, supply chain, and drug product considerations early are better positioned as they move toward clinical and commercial stages.
As demand for ADCs continues to grow and the investment in manufacturing infrastructure is following. The remaining question is how effectively that complexity is managed at the program level.
At Pharmefex, we work with teams navigating exactly these challenges. Our group includes specialists with direct experience in antibody and ADC development/LNP conjugation, along with quality management systems, supply chain, and analytical development. This allows us to support programs from a practical CMC perspective, where decisions around conjugation, analytics, and supply chain are closely connected.
We support clients through the development and regulatory process by providing integrated program oversight, where complex considerations are managed across antibody, linker, payload, and drug product activities. Changes in raw materials or upstream processes are assessed for downstream impact before they are implemented, helping maintain consistency as programs scale.
For teams working on ADCs, this level of coordination tends to make a difference when moving toward IND and beyond. The complexity is inherent to the modality. How it is managed determines how smoothly a program progresses.
#ADC #Biotech #Pharma #CMC #DrugDevelopment #AntibodyDrugConjugates #Manufacturing #CDMO #Quality #RegulatoryStrategy #Pharmefex #consulting #management #programmanagement #DahliaConsulting